Enzymatica AB (publ) (STO:ENZY)
1.880
+0.015 (0.80%)
Jul 24, 2026, 4:27 PM CET
Enzymatica AB Earnings Call Transcripts
Fiscal Year 2025
-
Recent independent studies confirm ColdZyme significantly reduces the duration and severity of upper respiratory infections by lowering viral load, as shown in both athlete-based and cell culture models. The product demonstrated strong efficacy and safety, with results expected to apply to the general population.